Breaking Barriers: Unleashing the Potential of ABO Blood Group Antigen Therapy in the Battle against Solid Tumors

Abstract

With the escalating economic burden of tumors, there is an urgent imperative to develop novel therapies. Activation of complement to eliminate tumors proves to be an effective approach. ABO blood group antibodies, naturally present in the body, activate the immune system by recognizing blood group antigens, resulting in the lysis and demise of red blood cells. Similarly, ABO blood group antigens can activate the human immune response and exhibit anti-tumor effects. By leveraging the immune properties of blood group antibodies in tumor treatment, a mechanism akin to the destruction of red blood cells in blood group incompatibility can be employed to eradicate tumor cells. This approach holds promise as a fresh avenue for tumor treatment and prevention of resistance.